May 31 (Reuters) - Celator Pharmaceuticals Inc
* Jazz Pharmaceuticals to acquire Celator for $30.25 per share
* Jazz Pharma expects to finance deal with a combination of cash on hand and borrowings under its senior secured credit facility
* Deal to add Vyxeos, to Jazz Pharmaceuticals’ portfolio
* Deal for about $1.5 billion
* Transaction expected to be accretive to non-gaap adjusted eps beginning in 2018 and beyond for Jazz Pharma
* Jazz Pharmaceuticals and Celator Pharmaceuticals announce agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.